Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12 month price objectives for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $28.00 to $75.00. On average, they anticipate the company's share price to reach $56.08 in the next year. This suggests a possible upside of 37.8% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $50.59 at the beginning of 2024. Since then, IONS shares have decreased by 19.6% and is now trading at $40.68.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. The company had revenue of $325 million for the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 90.29% and a negative net margin of 46.32%. The business's quarterly revenue was up 113.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.37) EPS.

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Invesco Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).

Ionis Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.15%), International Assets Investment Management LLC (0.01%), Diversified Trust Co (0.00%), Handelsinvest Investeringsforvaltning (0.00%), Sunbelt Securities Inc. (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Baroldi, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen.
View institutional ownership trends.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.